Ribosome-associated Quality Control (RQC) is a conserved cellular machinery that resolves translational stalls on ribosomes, preventing the production of truncated, toxic protein fragments. Mutations in RQC components—including Listerin (LTN1), Rqc2, and the C-terminal Domain (CTD) of ZNF598—are directly linked to familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This therapy proposes enhancing RQC activity to clear stalled translation complexes, reduce toxic protein fragment burden, and restore proteostasis in neurodegenerative conditions.
When a ribosome stalls during translation—due to mRNA damage, codon depletion, or problematic nascent chains—the RQC takes over:
- Detection: ZNF598 (aka GIGYF2) and eIF2A sense ribosomal collision
- Annotation: Rqc2 (NEMF) binds the 60S subunit, adding C-terminal alanine and threonine (CAT) tails via ribosomal protein L10 (RPL10/uL16)
- Resolution: Listerin (LTN1) functions as an E3 ubiquitin ligase to ubiquitinate the nascent chain
- Clearance: The tagged nascent chain is extracted and degraded by the proteasome
Genetic evidence directly implicates RQC dysfunction in neurodegeneration:
- Listerin (LTN1) mutations: Frameshift mutations near the C-terminus cause autosomal recessive ALS (MND/ALS type 6)
- Rqc2 (NEMF) variants: Associated with ALS-FTD spectrum disorders through impaired CAT-tailing
- ZNF598/GIGYF2: Variants linked to neurodevelopmental delay and Parkinson's disease
- RPL10/uL16: Mutations cause X-linked syndromic intellectual disability with motor phenotypes
RQC failure produces two classes of toxic products: (1) truncated proteins from partially translated mRNAs and (2) CAT-tailed aggregation-prone proteins from Rqc2 activity on the nascent chain.
Target: ZNF598-CTD allosteric modulators, Listerin RING domain activators
Approach:
- Screen for small molecules that increase ZNF598 autophosphorylation or Listerin ubiquitination activity
- Target RQC with compounds that promote ribosomal collision resolution
- Enhance Ltn1-RING activity to increase ubiquitination flux through the pathway
Precedent: Similar screens for E3 ligase activators (e.g., MLN4924 inhibits NEDD8-activating enzyme but activates certain ligases via substrate stabilization)
Target: Rqc2 (NEMF) interaction interfaces
Approach:
- Stabilize Rqc2-60S interaction to ensure complete CAT-tailing
- Prevent Rqc2 aggregation by small molecules or targeted protein degradation
- Promote productive extraction of CAT-tailed proteins
Mechanism: Enhanced CAT-tailing marks more nascent chains for proteasomal degradation, reducing accumulation of toxic fragments
Target: HBS1L-ABCE1 splitting complex
Approach:
- Increase HBS1L GTPase activity to accelerate ribosome release
- Enhance ABCE1 ATPase activity for efficient ribosome splitting
- Promote Dom34/Hbs1 recruitment to stalled complexes
Benefit: Faster resolution of collisions before RQC machinery is overwhelmed
Target: Listerin (LTN1), Rqc2 (NEMF), ZNF598
Approach:
- AAV-mediated overexpression of wild-type Listerin in motor neurons and cortical neurons
- Viral delivery of ZNF598 to restore collision-sensing capacity
- CRISPR activation (CRISPRa) of endogenous RQC genes
Priority: Loss-of-function ALS/FTD mutations (particularly recessive LTN1) are the primary indication
- Direct genetic validation: Listerin (LTN1) recessive mutations cause ALS
- Impaired CAT-tailing in NEMF variant carriers
- RQC overload from C9orf72 DPR toxicity creates dependency on RQC machinery
- Score contribution: 10/10 for ALS, 10/10 for FTD
- Ribosomal stalling increases in AD brain (tau phosphorylation affects translation)
- RQC dysfunction could contribute to Aβ and tau fragment accumulation
- Amyloid precursor protein (APP) contains rare codons that naturally stall ribosomes
- Score contribution: 7/10 for AD
- α-synuclein (SNCA) mRNA contains secondary structures that slow translation
- Translation stalling increases oxidative stress and protein aggregation
- RQC overload from α-syn overexpression may create vulnerability
- Score contribution: 7/10 for PD
- RQC efficiency declines with age (proteostasis network decline)
- Accumulation of truncated proteins is a hallmark of aged neurons
- Score contribution: 8/10 for aging
| Dimension |
Score (0-10) |
Rationale |
| Novelty |
9 |
Direct RQC targeting for neurodegeneration is essentially unexplored clinically |
| Mechanistic Rationale |
8 |
Strong genetic evidence (LTN1, NEMF, ZNF598); clear biochemical mechanism |
| Root-Cause Coverage |
8 |
Addresses proteostasis at the translational level, upstream of aggregation |
| Delivery Feasibility |
5 |
Gene therapy (AAV) for motor neurons is established (Spinraza, etc.); small molecules harder to design |
| Safety Plausibility |
7 |
RQC is essential but not rate-limiting; partial enhancement likely safe |
| Combinability |
8 |
Synergizes with proteasome enhancers, autophagy inducers, and protein synthesis inhibitors |
| Biomarker Availability |
6 |
CAT-tailed protein fragments in CSF as candidate biomarker; not yet clinically validated |
| De-risking Path |
7 |
Drosophila models available; primary neurons from patient iPSCs accessible |
| Multi-disease Potential |
8 |
ALS/FTD primary, AD/PD secondary, aging universal |
| Patient Impact |
7 |
ALS/FTD patients have highest unmet need; disease-modifying potential |
Total Score: 73/100
- M1: Validate RQC component expression in post-mortem ALS, AD, PD brain tissue (RNAscope, western blot)
- M2: iPSC-derived motor neurons from LTN1/NEMF mutation carriers: measure CAT-tailed proteins, truncated protein accumulation
- M3: Develop AlphaLISA or SIMOA assay for CAT-tailed protein fragments in human CSF
- M4: DrosophilaALS model (LTN1 knockdown) to confirm truncated protein toxicity and rescue by RQC enhancement
Academic centers: Columbia University (ALS iPSC core), UCSF (neurodegeneration models), University of Edinburgh (RQC biochemistry)
¶ Phase 2: Small Molecule and Gene Therapy Development (24 months, $8-12M)
- M1: High-throughput screen for Listerin RING domain activators (FRET-based ubiquitination assay)
- M2: Develop AAV9-LTN1 construct for CNS delivery (validates against Spinraza's precedent)
- M3: Off-target profiling of hit compounds
- M4: Dose-response studies in primary neurons and human iPSC-derived motor neurons
Companies for partnership: uniQure (AAV-LTN1), Denali Therapeutics (biologics for neurodegeneration), Calico (aging targets)
- M1: GLP toxicology (AAV9-LTN1: NHP studies)
- M2: GMP manufacturing for lead compound or gene therapy
- M3: IND submission
Estimated total: $20-30M, 54 months to IND
¶ Key Risks and Mitigation
| Risk |
Likelihood |
Impact |
Mitigation |
| RQC enhancers cause off-target translation inhibition |
Medium |
High |
Wide therapeutic window expected; titrate carefully |
| AAV9 delivery insufficient for cortical neurons |
Medium |
High |
Use novel capsids (AAV-PHP.eB, AAV-F travasculature) |
| CAT-tailing enhancement produces new toxic species |
Low |
High |
Monitor in Phase 1-2 assays |
| Limited commercial incentive (small patient population) |
Medium |
Medium |
Pursue orphan designation; combination with larger indications |
- Validate RQC impairment in ALS-FTD patient iPSC-derived motor neurons (measure CAT-tailed proteins by western blot with anti-alanine antibody)
- Test whether Listerin overexpression rescues neurodegeneration phenotypes in patient neurons
- Screen for small molecules that increase Listerin ubiquitination activity in vitro
- Develop mass spectrometry assay for RQC-generated truncated proteins in human brain tissue
- Phase 1/2a trial design: AAV9-LTN1 intrathecal administration in ALS patients with confirmed LTN1/NEMF mutations
- Biomarker: measure CAT-tailed protein fragments in CSF before and after treatment
- Primary endpoint: survival, ALSFRS-R decline rate, CSF biomarkers
- uniQure (AAV gene therapy for neurodegenerative diseases)
- Denali Therapeutics (precision medicine approach for neurodegenerative diseases)
- Roche/Genentech (neuroscience pipeline, ALS/FTD focus)
- ALS Association Therapeutic Idea Award
- NINDS R01: Gene therapy for rare forms of ALS
- The Wellcome Trust: Translation of RQC modulators